CXCR5 Gene

cxcr5
Gene Symbol	CXCR5
Full Name	C-X-C Chemokine Receptor Type 5
Aliases	CD185, BLR1, Munchen's, RB1
Chromosomal Location	11q23.3
NCBI Gene ID	[935](https://www.ncbi.nlm.nih.gov/gene/935)
OMIM	[601745](https://www.omim.org/entry/601745)
Ensembl ID	[ENSG00000169679](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000169679)
UniProt ID	[P41970](https://www.uniprot.org/uniprot/P41970)
Gene Type	Protein coding
Gene Family	Chemokine receptors (GPCR family)
Cell Type	CXCR5 Expression
Naive B cells	High
Memory B cells	Moderate
Marginal zone B cells	High
Tfh cells	High
Pre-Tfh cells	Moderate
NK T cells	Low
Dendritic cells (follicular)	Moderate
Condition	CXCR5 Expression
Multiple Sclerosis	High
Alzheimer's Disease	Moderate
Parkinson's Disease	Low-Moderate
Stroke	Moderate
MS Disease Type	CXCR5/CXCL13 Role
Relapsing-remitting MS	High
Secondary progressive	Very High
Primary progressive	Moderate-High
Clinically isolated syndrome	High
AD Feature	CXCR5 Association
Amyloid plaques	CXCR5+ B cells surrounding plaques
Neurofibrillary tangles	Unknown
Neuroinflammation	CXCL13 elevated in brain/CSF
Cognitive decline	CSF CXCL13 correlates with decline
Condition	CXCR5/CXCL13 Involvement
Guillain-Barré Syndrome	Moderate
Myasthenia Gravis	High
Amyotrophic Lateral Sclerosis	Preliminary
Stroke	Moderate
Epilepsy	Preliminary
Associated Diseases	Autoimmune, Cancer, Colorectal Cancer, Tumor
KG Connections	13 edges

Overview

CXCR5 (C-X-C Chemokine Receptor Type 5, also known as CD185, BLR1, and Munchen’s) is a G protein-coupled receptor that binds specifically to the chemokine CXCL13 (also known as BLC, BCA-1, and B lymphocyte chemoattractant). Originally identified as essential for B cell trafficking to B cell follicles and germinal centers, CXCR5 and the CXCL13-CXCR5 axis have emerged as critical players in neuroinflammation, autoimmune diseases, and potentially in neurodegenerative conditions including Alzheimer’s disease, Parkinson’s disease, and multiple sclerosis [1][2].

The CXCL13-CXCR5 signaling axis orchestrates the organization of secondary lymphoid tissues, B cell follicle formation, and follicular helper T cell (Tfh) development. In the nervous system, this axis contributes to neuroinflammation through the recruitment of B cells and Tfh cells to the central nervous system, the formation of ectopic lymphoid structures in meninges, and the promotion of autoantibody production. This page covers the gene’s normal function, molecular signaling mechanisms, disease associations, expression patterns in the brain, and therapeutic targeting strategies relevant to neurodegeneration.

Gene Overview

Gene Structure

The CXCR5 gene spans approximately 35 kb and consists of 5 exons encoding a 7-transmembrane domain GPCR of 372 amino acids. The gene is located on chromosome 11q23.3, a region that has been implicated in various malignancies and autoimmune diseases. The promoter region contains binding sites for multiple transcription factors including STAT5, BCL6, and NF-κB, reflecting its complex regulation in different immune cell types [3].

Protein Structure and Function

Receptor Architecture

CXCR5 is a Class A G protein-coupled receptor consisting of:

N-terminal extracellular domain (41 aa): Contains the chemokine-binding site with high specificity for CXCL13
Seven transmembrane domains (TM1-TM7): Each ~20-25 aa, forming the characteristic GPCR bundle
Three extracellular loops (ECL1-ECL3): ECL2 is the largest and contains critical ligand-binding residues
Three intracellular loops (ICL1-ICL3): Couple to G proteins
C-terminal intracellular tail: Contains serine/threonine residues for phosphorylation and β-arrestin recruitment

The receptor binds CXCL13 with high affinity (Kd ~ 0.1-1 nM) and exhibits no significant binding to other chemokines. CXCL13 is unique among homeostatic chemokines in its specific pairing with CXCR5, making this axis particularly attractive for selective modulation [4].

Signaling Mechanisms

Upon CXCL13 binding, CXCR5 activates multiple intracellular signaling pathways:

G protein-dependent signaling:

Gα_i/o pathway: Inhibits adenylate cyclase, reducing cAMP levels
Gβγ subunits: Activate PI3K and MAPK pathways, leading to cell migration
PLCβ activation: Generates IP3 and DAG, mobilizing calcium

β-arrestin-dependent signaling:

Receptor phosphorylation triggers β-arrestin recruitment
β-arrestin scaffolds MAPK components (ERK, JNK, p38)
Promotes receptor internalization and desensitization

Key downstream pathways:

PI3K/Akt: Survival and migration signals
MAPK/ERK: Cell proliferation and differentiation
NF-κB: Inflammatory gene transcription
mTOR: Metabolic reprogramming in Tfh cells

The CXCR5 signaling axis is essential for the formation and maintenance of B cell follicles and germinal centers [5].

Normal Physiological Functions

B Cell Trafficking and Germinal Center Formation

CXCR5 is essential for B cell migration and lymphoid tissue organization:

B cell follicle homing: CXCR5 expression on naive B cells guides them to B cell follicles in secondary lymphoid organs. The CXCL13 gradient created by follicular dendritic cells (FDCs) attracts CXCR5+ B cells, establishing the B cell follicle structure.

Germinal center formation: After antigen engagement, B cells upregulate CXCR5 and migrate to the follicular zone, where they interact with Tfh cells. This migration is essential for:

Germinal center formation
Somatic hypermutation
Class-switch recombination
Affinity maturation

Marginal zone B cells: CXCR5 is expressed on marginal zone B cells, which are specialized for T-independent antibody responses to blood-borne antigens.

Follicular Helper T Cell (Tfh) Development and Function

CXCR5 is a defining marker of Tfh cells and critical for their development:

Tfh differentiation: During CD4+ T cell activation, the balance between CXCR5 and CCR7 expression determines Tfh vs. non-Tfh fate. High CXCR5/low CCR7 favors Tfh differentiation.

Tfh migration: Tfh cells use CXCR5 to migrate into B cell follicles, where they provide help to B cells through:

IL-21 and IL-4 secretion
CD40L expression
Cytokine receptor signaling

Germinal center maintenance: Tfh cells are essential for germinal center maintenance, affinity selection, and memory B cell generation.

Lymphoid Organogenesis

During development, CXCR5 is expressed on lymphoid tissue inducer (LTi) cells and is required for:

Formation of lymph nodes
Peyer’s patch development
Splenic white pulp organization
Nasal-associated lymphoid tissue (NALT) formation [6]

Expression Pattern

Immune System Expression

Central Nervous System Expression

In the healthy brain, CXCR5 expression is minimal. However, under pathological conditions:

B cells: CXCR5+ B cells are the primary CXCR5-expressing immune cells in the CNS. They accumulate in:

Perivascular spaces
Meningeal infiltrates
Ectopic lymphoid structures (in chronic disease)

Tfh-like cells: CXCR5+ CD4+ T cells with Tfh-like phenotypes have been detected in:

MS lesions
Meningeal infiltrates
Cerebrospinal fluid

Microglia: Some studies report low-level CXCR5 expression on microglia in demyelinating lesions, though this remains controversial.

Astrocytes: CXCL13 (the ligand) is expressed by astrocytes in various neurological conditions, creating a chemotactic gradient.

Expression in Disease States

Disease Associations

Multiple Sclerosis

The CXCL13-CXCR5 axis is strongly implicated in multiple sclerosis pathogenesis:

B cell recruitment: CXCL13 is highly expressed in MS lesions, particularly in active demyelinating areas. The chemokine gradient recruits CXCR5+ B cells to the CNS, where they contribute to:

Autoantibody production
Antigen presentation
Cytokine secretion
Formation of ectopic lymphoid structures

Ectopic lymphoid structures: B cells and Tfh-like cells form ectopic lymphoid-like structures in the meninges of progressive MS patients. CXCL13 expression by meningeal cells and astrocytes drives the organization of these structures, which correlate with:

More severe disease
Younger age at onset
Higher disability progression
Compartmentalized inflammation

Therapeutic implications: B cell depletion therapies (rituximab, ocrelizumab) may work in part by removing CXCR5+ B cells from CNS compartments. CXCR5 antagonists are being explored as targeted therapies [7][8].

Alzheimer’s Disease

Emerging evidence links CXCR5 to Alzheimer’s disease pathogenesis:

B cell infiltration: CXCR5+ B cells infiltrate AD brain and accumulate around amyloid plaques. These cells may contribute to:

Local cytokine production
Antigen presentation to T cells
Potential autoantibody production against brain antigens

Neuroinflammation: The CXCL13-CXCR5 axis contributes to chronic neuroinflammation in AD:

Promotes recruitment of peripheral immune cells to the brain
May support ectopic lymphoid-like structures in meninges
Contributes to cytokine cascade

Cognitive decline: Correlative studies suggest associations between CSF CXCL13 levels and cognitive decline in AD patients [9][10].

Parkinson’s Disease

CXCR5 involvement in Parkinson’s disease is emerging:

Dopaminergic regions: CXCR5+ B cells have been detected in the substantia nigra of PD patients, though their role is unclear.

Neuroinflammation: CXCL13 expression is elevated in PD models and some patient samples. The axis may contribute to neuroinflammation through B cell recruitment.

Autoimmunity: Some studies suggest B cell autoimmunity in PD, and CXCR5+ Tfh cells may promote such responses.

Other Neurological Conditions

Autoimmune and Inflammatory Conditions

Beyond the nervous system, CXCR5 is implicated in:

Autoimmune diseases: Tfh cells expressing CXCR5 drive autoantibody production in:

Systemic lupus erythematosus (SLE)
Rheumatoid arthritis
Autoimmune hepatitis
Type 1 diabetes

Lymphoma: CXCR5 is expressed on certain B cell lymphomas, particularly:

Follicular lymphoma
Burkitt lymphoma
Some diffuse large B cell lymphomas

Immunodeficiency: CXCR5 deficiency leads to impaired B cell follicle formation and immunodeficiency [11][12].

Therapeutic Targeting

CXCR5 Antagonists

Several CXCR5-targeting strategies are in development:

Monoclonal antibodies:

Anti-CXCR5 antibodies have been used in preclinical models
Antibody-dependent cellular cytotoxicity (ADCC) may deplete CXCR5+ B cells

Small molecule antagonists:

Various CXCR5 antagonists have been identified
Most are in early preclinical development

Alternative approaches:

CXCL13 neutralizing antibodies
CXCL13 receptor-Fc fusion proteins (decoy receptors)

B Cell-Targeted Therapies

While not directly targeting CXCR5, several approved therapies affect CXCR5+ cells:

Rituximab: Anti-CD20 antibody depletes B cells, including CXCR5+ populations. Used in MS, NHL, RA.

Ocrelizumab: Humanized anti-CD20 antibody approved for MS. Highly effective in RRMS and PPMS.

Ofatumumab: Anti-CD20 antibody with subcutaneous administration. Approved for MS.

Eculizumab/Ravulizumab: Anti-C5 antibodies used in PNH and MG, affect complement-mediated B cell functions [13].

Animal Models

Knockout Mice

CXCR5 knockout mice (Cxcr5-/-) exhibit:

Complete absence of B cell follicles in spleen and lymph nodes
Impaired germinal center formation
Loss of Tfh cells
Defective antibody responses
Spontaneous development of autoimmunity in some backgrounds

Transgenic Models

CXCR5 overexpression in mice leads to:

Enhanced B cell follicle formation
Increased Tfh cell numbers
Spontaneous autoimmunity in some backgrounds

EAE Model

The EAE model (mouse model of MS) has been used to study CXCR5:

CXCL13 expression in spinal cord correlates with disease severity
CXCR5 deficiency reduces B cell infiltration
Tfh cells contribute to disease progression

Key Publications

External Links

Sister wikis (recently updated · no domain on this page)

Recent activity here

No recent events touching this page.